Clinical efficacy of ambroxol intravenous and budesonide atomizing inhalation combined with cefodizime on infantile pneumonia
10.3969/j.issn.1005-1678.2016.06.24
- VernacularTitle:氨溴索静滴、布地奈德雾化联合头孢地嗪治疗小儿肺炎的临床疗效
- Author:
Yan WANG
;
Lizhu CHEN
;
Yixue ZHENG
;
Jiekui CHEN
- Publication Type:Journal Article
- Keywords:
ambroxol;
budesonide.cefodizime;
infantile pneumonia;
PCT;
IL-6
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(6):88-90
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of ambroxol intravenous and budesonide atomizing inhalation combined with cefodizime on infantile pneumonia and its effects of serum PCT, IL -6 levels and related immune factors.Methods 95 children with pneumonia from May 2013 to October 2015 in Sanya Hospital of Traditional Chinese Medicine were collected and randomly divided into control group(n=47) and experiment group (n=48), two groups were treated by clinical routine treatment, such as antipyretic, anti-inflammatory, strengthen nutrition in children, and control group were added with ambroxol, iv, qd; experiment group were added cefodizime on the basis of control group, the course was one week.Clinical efficacy,serum PCT, IL -6 levels, immune factors and adverse reactions were observed and compared.Results The serum PCT and IL -6 levels of experiment group were lower than control group post-treatment, and CD4 +, CD4 +/CD8 +levels were higher than control group, CD8 +level was lower than control group, the differences were all significant (P<0.05).The effective rate of experiment group was 93.75%, higher than 80.85% of control group(P<0.05).Incidence of adverse reactions between two groups had no statistical difference.Conclusion Ambroxol intravenous and budesonide atomizing inhalation combine with cefodizime in treatment of infantile pneumonia has better clinical efficacy, could effectively reduce the serum PCT and IL-6 levels, effectively improve the clinical symptoms.
